WallStSmart

Becton Dickinson and Company (BDX)vsICU Medical Inc (ICUI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 883% more annual revenue ($21.92B vs $2.23B). BDX leads profitability with a 8.0% profit margin vs 0.0%. ICUI appears more attractively valued with a PEG of 0.07. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

ICUI

Hold

47

out of 100

Grade: D+

Growth: 2.0Profit: 4.0Value: 4.7Quality: 6.3
Piotroski: 5/9Altman Z: 1.63
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued
ICUISignificantly Overvalued (-73765.0%)

Margin of Safety

-73765.0%

Fair Value

$0.20

Current Price

$131.38

$131.18 premium

UndervaluedFair: $0.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

ICUI2 strengths · Avg: 9.0/10
PEG RatioValuation
0.0710/10

Growing faster than its price suggests

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

ICUI4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.634/10

Distress zone — elevated risk

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
4.8%3/10

Operating margin of 4.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : ICUI

The strongest argument for ICUI centers on PEG Ratio, Price/Book. PEG of 0.07 suggests the stock is reasonably priced for its growth.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : ICUI

The primary concerns for ICUI are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 4313.3x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

ICUI carries more volatility with a beta of 0.81 — expect wider price swings.

BDX is growing revenue faster at 1.6% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

ICU Medical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.

Want to dig deeper into these stocks?